Renal Cell Carcinoma

Immune checkpoint inhibitors have antitumor activity in gastric, esophageal cancers

Publish date: January 28, 2016

Key clinical point: Nivolumab and pembrolizumab appear active and well tolerated in patients with previously treated esophagogastric cancers....

Publish date: September 8, 2015

Key clinical point: An individualized approach to surveillance after surgical resection in patients with renal cell carcinoma may provide better...

Publish date: March 23, 2015

Key clinical point: A majority of previously treated patients with renal cell carcinoma benefited from nivolumab. Major finding: At a median 45-...